


Five-year composite outcome similar for TiNO-coated stent, everolimus-eluting stents

May 30 2023, by Elana Gotkine



For patients with acute coronary syndrome (ACS), titanium-nitride-

oxide (TiNO)-coated stents do not improve long-term outcomes in terms of a composite outcome over third-generation everolimus-eluting stents (EES), according to a study published online May 19 in *JAMA Cardiology* to coincide with EuroPCR, the official annual meeting of the European Association of Percutaneous Cardiovascular Interventions, held from May 14 to 17 in Paris.

Frederic Bouisset, M.D., from the Cardiovascular Center Aalst in Belgium, and colleagues compared the rate of the main composite outcome of cardiac death, [myocardial infarction](#) (MI), or ischemia-driven target lesion revascularization at five years in a multicenter randomized trial involving [patients](#) with ACS with at least one de novo lesion randomly assigned to receive either a TiNO-coated stent or a third-generation EES (989 and 502 patients, respectively).

The researchers found that the main composite outcome events occurred in 11.2 and 12.0 percent of patients in the TiNO and EES groups, respectively (hazard ratio, 0.94 [95 percent confidence interval, 0.69 to 1.28]; P = 0.69). In the TiNO and EES arms, respectively, the rate of cardiac death was 0.9 versus 3.0 percent (hazard ratio, 0.30 [0.13 to 0.69] P = 0.005); MI was 4.6 versus 7.0 percent (hazard ratio, 0.64 [0.41 to 0.99]; P = 0.049); [stent thrombosis](#) was 1.2 versus 2.8 percent (hazard ratio, 0.43 [0.20 to 0.93] P = 0.034); and target lesion revascularization was 7.4 versus 6.4 percent (hazard ratio, 1.16 [0.77 to 1.76]; P = 0.47).

"A significant reduction in cardiac death, MI, and stent thromboses in favor of TiNO-coated stents was offset by numerically higher rates of ischemia-driven target lesion revascularization," the authors write.

Several authors disclosed ties to pharmaceutical and medical device companies, including Hexacath, which funded the study.

More information: Frederic Bouisset et al, Titanium-Nitride-

Oxide-Coated vs Everolimus-Eluting Stents in Acute Coronary Syndrome, *JAMA Cardiology* (2023). DOI: [10.1001/jamacardio.2023.1373](https://doi.org/10.1001/jamacardio.2023.1373)

[More Information](#)

Copyright © 2023 [HealthDay](#). All rights reserved.

Citation: Five-year composite outcome similar for TiNO-coated stent, everolimus-eluting stents (2023, May 30) retrieved 25 April 2024 from <https://medicalxpress.com/news/2023-05-five-year-composite-outcome-similar-tino-coated.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.